Results 1 to 10 of about 3,549 (185)

Impact of single dose of pegfilgrastim on peripheral blood stem cell harvest in patients with multiple myeloma or malignant lymphoma [PDF]

Scientific Reports
This phase 2 study evaluated the impact of pegfilgrastim, a single-dose, long-acting granulocyte colony-stimulating factor, on the steady-state mobilization of hematopoietic stem cells into peripheral blood in patients with multiple myeloma (MM) or ...
Hideki Goto, Masashi Sawa, Shin-ichiro Fujiwara, Masaki Ri, Tadao Ishida, Masahiro Takeuchi, Kenji Ishitsuka, Masako Toyosaki, Kazutaka Sunami, Junichi Tsukada, Takashi Sonoki, Aiko Shimogomi, Yuki Ichihashi, Yoshiumi Ouchi, Toshihiro Miyamoto, Masayuki Hino, Yoshinobu Maeda, Takanori Teshima   +17 more
doaj   +3 more sources

Successful Treatment of Granulocyte Colony‐Stimulating Factor‐Related Aortitis in Prostate Cancer [PDF]

IJU Case Reports
Introduction The frequency of granulocyte colony‐stimulating factor‐related aortitis is low. We report a case of successful corticosteroid treatment in a patient with prostate cancer who developed aortitis following pegfilgrastim administration.
Shota Yamada, Kota Amamoto, Nobuhide Maekawa, Kazusato Hara, Takahisa Iwata, Yushi Imasato, Tomohiro Matsuo, Masataka Furukawa, Ryoichi Imamura   +8 more
doaj   +3 more sources

Efficacy and Safety of Pegfilgrastim in Patients With Severe Congenital Neutropenia [PDF]

eJHaem
Background Severe congenital neutropenia (SCN) is commonly treated with granulocyte colony‐stimulating factor (G‐CSF) to reduce neutropenia and the associated risk of infections.
Mahdiyeh Movahedi, Leila Moradi, Zahra Alizadeh, Mojtaba Tabatabaei Yazdi, Shirin Dehbashi, Raheleh Shokouhi Shoormasti, Marzieh Maddah, Anahita Razaghian, Amir Ali Hamidieh, Mansoureh Shariat, Massoud Houshmand, Atefe Alirezaee, Maryam Akbari, Mohammad Reza Fazlollahi, Zahra Pourpak   +14 more
doaj   +2 more sources

Pegfilgrastim

Reactions Weekly
Patel P, King N, Jacobs TF.
europepmc   +10 more sources

A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis [PDF]

EClinicalMedicine, 2022
Summary: Background: In trials conducted in India, recombinant granulocyte colony stimulating factor (GCSF) improved survival in alcohol-associated hepatitis (AH).
John A. Tayek, Andrew A. Stolz, Danh V. Nguyen, M. Wayne Fleischman, John A. Donovan, Joseph M. Alcorn, Daniel C-K. Chao, Aliya Asghar, Timothy R. Morgan, Divya Birudaraju, Greg Botwin, Hema Buddha, Lavanya Cherukuri, Sheena Cruz, Monique French, Rachel Gonzalez, Jessica Gozum, Rebecca Gutierrez, Sajad Hamal, Preston Head, Carol Jones, Neil Kaplowitz, Robert Lee, Lauren MacHarg, Susan Milstein, Yuxin Ouyang, Christy Rico, Cory Zarick   +27 more
doaj   +2 more sources

Pegfilgrastim-related thoracic aortitis: A case report and literature review

Current Problems in Cancer: Case Reports, 2023
Pegfilgrastim can prevent febrile neutropenia during chemotherapy and helps maintain treatment intensity. Aortitis is a rare and serious adverse event associated with pegfilgrastim therapy. The mechanism of pegfilgrastim-related aortitis is unknown.
Chikako Sekine, Sasagu Kurozumi, Hirotoshi Kawashima, Koichi Hirose, Jun Horiguchi   +4 more
doaj   +1 more source

Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: a systematic review of efficacy, effectiveness and safety

BMC Cancer, 2021
Background Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), is commonly used to prevent febrile neutropenia (FN), a potentially life-threatening complication, following myelosuppressive chemotherapy.
Reshma Mahtani, Jeffrey Crawford, Sinéad M. Flannery, Tatiana Lawrence, Jennifer Schenfeld, Prasad L. Gawade   +5 more
doaj   +1 more source

Comparison of Efficacy and Safety of Lupin’s Pegfilgrastim with Neulastim® as an Adjunct to Chemotherapy in Patients with Non Myeloid Malignancies: A Randomised Phase III Clinical Study [PDF]

Journal of Clinical and Diagnostic Research, 2022
Introduction: Pegfilgrastim is indicated in patients receiving myelosuppressive anticancer drugs to reduce the Duration of Severe Neutropenia (DSN) and incidence of Febrile Neutropenia (FN).
Minish Jain, Sharad Desai, Rajnish Nagarkar, Rakesh Neve, Unmesh Takalkar, Dhananjay Bakhle, Chirag Shah   +6 more
doaj   +1 more source

Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: A review of adherence to present guidelines for usage

Cancer Treatment and Research Communications, 2021
Evidence-based US guidelines provide recommendations for the use of granulocyte colony-stimulating factor (G-CSF) as supportive therapy in patients with cancer receiving chemotherapy.
Jeffrey Crawford, Donald C. Moore, Vicki A. Morrison, David Dale   +3 more
doaj   +1 more source

Pegfilgrastim on febrile neutropenia in pediatric and adolescent cancer patients: a systematic review and meta-analysis

Hematology, 2023
Objectives There is no meta-analysis about the effects of pegfilgrastim on the occurrence of febrile neutropenia (FN) in pediatric/adolescent cancer patients.
Xia Zhu, Weiling Zhang, Yi Zhang, Yizhuo Wang, Huimin Hu, Jing Li, Yan Zhou, Tao Han, Dongsheng Huang   +8 more
doaj   +1 more source